Trends in Research on Autoimmune Liver Disorders and Gut Microbiota (1989–2025): A Bibliometric and Visualization Study Utilizing the Web of Science Core Collection Database - Scorecard - MDSpire
Advertisement
Trends in Research on Autoimmune Liver Disorders and Gut Microbiota (1989–2025): A Bibliometric and Visualization Study Utilizing the Web of Science Core Collection Database
Clinical Scorecard: Trends in Research on Autoimmune Liver Disorders and Gut Microbiota (1989–2025): A Bibliometric and Visualization Study Utilizing the Web of Science Core Collection Database
Gut microbiota dysbiosis affecting the gut-liver axis, disruption of intestinal barrier, microbial metabolites entering liver via enterohepatic circulation, activating hepatic immune responses and promoting inflammation and fibrosis
Target Population
Patients with autoimmune liver diseases globally, with increasing incidence and prevalence
Care Setting
Specialized hepatology and immunology clinical settings focusing on chronic liver disease management
Key Highlights
AILD prevalence is rising globally, with AIH and PBC being more common than PSC and IgG4-SC.
Gut microbiota alterations in AILD include reduced diversity, increased harmful bacteria, and decreased protective and short-chain fatty acid-producing bacteria.
Emerging research uses Mendelian randomization to suggest causal roles of gut microbiota in AILD pathogenesis.
Guideline-Based Recommendations
Diagnosis
Consider comprehensive clinical evaluation including autoimmune markers and liver histology for AILD diagnosis.
Recognize the potential role of gut microbiota profiling as an adjunctive research tool in understanding disease mechanisms.
Management
Current management focuses on immunosuppressive therapies and symptom control.
Future therapeutic strategies may involve modulation of gut microbiota and its metabolites to target disease progression.
Monitoring & Follow-up
Regular monitoring for disease progression including liver fibrosis and cirrhosis development.
Surveillance for complications such as end-stage liver disease and need for transplantation.
Risks
Progression to liver fibrosis, cirrhosis, and end-stage liver disease if untreated or poorly controlled.
Heterogeneity in clinical presentation and treatment response necessitates individualized care.
Patient & Prescribing Data
Patients diagnosed with autoimmune liver diseases including AIH, PBC, PSC, and IgG4-SC.
While immunosuppressive treatments remain standard, emerging evidence supports exploring gut microbiota modulation as a potential adjunctive therapeutic approach.
Clinical Best Practices
Integrate multidisciplinary approaches combining hepatology, immunology, and microbiome research for comprehensive patient care.
Encourage longitudinal and large-cohort studies to better understand gut microbiota’s role in AILD.
Stay updated on emerging genetic and microbiome-based diagnostic and therapeutic tools.
The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.
